Excellent review

I am without words, so moved! This is such an amazing review of ANDROMEdA-SHOCK-2!! It is not only science, it is poetry!! Thanks, thanks, and thanks dear Rob (Crit Care Reviews)😍😍

44% of released incarcerated people in the U.S. are arrested within a year. 3 years? 68% 5 years? 77% Two factors consistently lower re-offense rates: - Education while incarcerated - Strong family communication Full article in comments @PrisonPolicy @ElizabethHolmes

What a wonderful, balanced and poetic post on AS2 "CRT, like a star, is not the destination but a guide for the journey. The voyage of precision resuscitation continues, steered now by a new light in the sky" Infinite thanks @CritCareReviews @AndromedaShock @JAMA_current

Our latest blog is out - Faith, Evidence and the Stars: The ANDROMEDA‑SHOCK‑2 Trial https://t.co/Yu9qoJa9Gr

Orgullo enorme de formar parte del estudio que redefine la reanimación en shock séptico. El ensayo internacional ANDROMEDA-SHOCK-2, publicado en @JAMA_current demuestra que una reanimación personalizada puede mejorar la supervivencia de pacientes críticos https://t.co/WdMDp18hdl

Highly, highly recommended. This was a great listen - loved heard the dissection of the trial and the new questions generated by this discussion. @edu_kattan @AndromedaShock @emcrit

⏱️🩸𝗧𝗶𝗲𝗺𝗽𝗼 𝗱𝗲 𝗹𝗹𝗲𝗻𝗮𝗱𝗼 𝗰𝗮𝗽𝗶𝗹𝗮𝗿 (𝗖𝗥𝗧)‼️ @Springer_Med @ClinMedJournals @yourICM 👇🏼👇🏼👇🏼👇🏼 📑🔗🔑🔓 https://t.co/9Kw8bk0J5O ⬇️⬇️⬇️⬇️ 🧵👇 ‼️Ha resurgido como herramienta dinámica para guiar la resucitación del shock séptico. 🔰Refleja el acoplamiento entre

ANDROMEDA-SHOCK-2が出版されてから、CRTそのものやCRTを指標にした循環管理が話題ですね！ でも世の中が熱狂している今こそ、冷静に考えてみませんか？ CRTを指標にした循環蘇生を検証したANDROMEDA-SHOCK-2は本当に "Less is more" を示した研究と言えるのでしょうか？ https://t.co/auDCe2U3fQ

If you can attend only one course this year, this is the one to attend to 👇

A nice chat with Scott Weingart (EmCrit) together with Eduardo Kattan digging deeper into the foundations and results of ANDROMEDA-SHOCK-2😍 https://t.co/OrpyLAnuf1

EMCrit Wee - @AndromedaShock 2 Explosion - An amazing discussion with the Lead Investigators. This conversation was educational and so enjoyable. Find out the intricacies of the study [#FOAMed for now] https://t.co/SeuHIm0jGu #edu_kattan

At this rate, the total number of prompts put into ChatGPT this *YEAR* will still be less than the total number of searches on Google *TODAY*. And today is a Saturday. I had a really interesting conversation with the head of growth for a Fortune 500 company this week. She said,

@AndromedaShock Thank you, Glenn! Always great to share ideas with you. Hope this simplified flow helps more teams in their daily practice

Our 6th Hemodynamic Monitoring and Tissue Perfusion Course (online, bilingual) is coming soon (Nov 19-21)! ANDROMEDA-SHOCK-2 will be extensively discussed there😍. Link in the poster below

@caru_fred Nice articles

Amazing work by these centers and teams!

Humans and AI are not that different. We are God's AI in a super complex, infinite system.

Great thread on MAP challenges in AS2 - almost half of the ones performed normalized CAP refill.

@khaycock2 @Rajiv_Sinanan @ThinkingCC @icmteaching @kyliebaker888 @ArgaizR @ABCDEcografia @MynephCC Thoughtful, patient-centered, physiology-driven medicine isn’t something our system tangibly rewards. Clinicians need incentives and quick-fixes, hospitals need metrics, and researchers are pressured to publish. For a few, the quiet satisfaction of doing right by the patient is

@edu_kattan @AndromedaShock @ThinkingCC @ross_prager Personalization is the way, simplicity is the goal, #ANDROMEDA2 aims to make it simple.

This is the beauty of hemodynamic personalization, isn't it? @AndromedaShock @ThinkingCC @jesus_nieves_a @ross_prager

Warriors Path to Restoration Dear Warrior, There are battles the world will never see, battles fought in silence, behind closed doors, and inside the mind long after the war has ended. This guide was created for you. Not as another program, not as another checklist, but as a

I am loving the discourse on ANDROMEDA-SHOCK 2 so far on #MedTwitter So much learning! My two cents: follow @ross_prager